Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Executive Summary

• Cardiol Therapeutics announced that the MAVERIC Phase III trial for recurrent pericarditis has surpassed the 50% patient‑enrollment mark.
• More than 15 leading U.S. cardiovascular centers are actively enrolling, with additional sites coming online in Europe and Canada; full enrollment is projected for Q2 2026.
• The milestone reduces execution risk for Cardiol’s lead registrational program and supports expectations that CardiolRx™ could become a differentiated oral therapy in a market dominated by biologics.

Key Details

• Enrollment Progress: >50% of the target ~110 patients enrolled across ~25 sites (U.S., Canada, Europe).
• Current Sites: 15+ U.S. cardiovascular centers actively enrolling; additional premier sites being activated in Europe and Canada.
• Projected Completion: Full enrollment expected Q2 2026; primary endpoint read‑out after six months of double‑blind treatment.
• Trial Design: Randomized, double‑blind, placebo‑controlled, multi‑center international Phase III study (MAVERIC). Primary endpoint – freedom from a new episode of recurrent pericarditis; secondary endpoints – days with minimal pain, pain score changes, CRP biomarker changes.
• Scientific Rationale: Builds on positive Phase II MAvERIC‑Pilot results showing rapid pain reduction, inflammation control, and lower recurrence rates.
• Strategic Context: Data from the ARCHER Phase II study in acute myocarditis further support CardiolRx™’s potential to address unmet needs and compete with biologics projected to generate >$800 M U.S. revenue in 2026.
• Future Development: Company also advancing CRD‑38 (subcutaneous formulation) for inflammatory heart disease, including heart failure; first‑in‑human studies planned.

Notable Quotes

• “Surpassing 50% enrollment … reflects both the high unmet medical need in recurrent pericarditis and the confidence investigators have in the scientific rationale and rigorous design of this pivotal trial.” – Dr. Andrew Hamer, Chief Medical Officer & Head of R&D
• “Data from the recent ARCHER study… reinforce our position that CardiolRx™ has the potential to meaningfully change the management of recurrent pericarditis.” – David Elsley, President & CEO

Materiality Assessment: Material – Positive (milestone reduces risk and signals progress toward a potentially high‑value product).